Investors in ImmunityBio Have a Chance to Lead a Significant Class Action Lawsuit

Investor Alert: ImmunityBio Class Action Lawsuit

March 27, 2026 - The Rosen Law Firm, recognized as a global leader in investor rights, announces the initiation of a class action lawsuit on behalf of shareholders of ImmunityBio, Inc. (NASDAQ: IBRX). The legal action centers around investors who purchased securities from January 19, 2026, to March 24, 2026, inclusive.

Why This Matters

The class action aims to address securities fraud allegations, highlighting claims that during the defined Class Period, the company and its executives, particularly Patrick Soon-Shiong, made misleading statements regarding the capabilities of Anktiva—the company's immunotherapeutic agent—resulting in material deception regarding ImmunityBio's business and operational prospects.

Investors who are planning to take part in the lawsuit have until May 26, 2026, to file for the position of lead plaintiff. This role is crucial as it represents the interests of all shareholders engaged in the case against ImmunityBio.

Steps for Affected Investors

Affected investors are encouraged to act swiftly if they wish to join the lawsuit. To participate, individuals can visit the Rosen Law Firm's dedicated page for this case at Rosen Legal or contact attorney Phillip Kim, Esq., at toll-free 866-767-3653 or via email at [email protected] for additional information. Joining this class action could entitle investors to financial compensation without any upfront costs, as the firm operates on a contingency fee basis.

About Rosen Law Firm

Rosen Law Firm has a distinguished history in securities class action litigation, boasting the largest settlement ever reached against a Chinese company. Their performance in the field has earned them numerous accolades, including recognition as a top firm repeatedly since 2013 and securing over $438 million for investors just in 2019. The firm's dedication to investors—alongside its expertise—provides a compelling reason for affected shareholders to consider representation through their platform.

Allegations of Misrepresentation

The essence of the legal complaint stems from allegations that ImmunityBio and its top representatives knowingly issued false and misleading statements about the capabilities of their product, Anktiva. The lawsuit asserts that these misleading declarations significantly impacted investor decisions during the Class Period, culminating in financial losses once the truth was revealed. As the truth emerged, investors left vulnerable incurred damage as a result of the companies’ actions.

Conclusion

For anyone who purchased ImmunityBio securities during the Class Action period, now is the ideal time to assess your situation and consider joining this significant lawsuit with the Rosen Law Firm. With pressing deadlines and the potential for financial recovery on the line, investors should take immediate action and consult legal expertise to safeguard their interests. Follow updates from Rosen Law Firm via their LinkedIn, Twitter, or Facebook accounts.